Press release
Alzheimer's Disease Market is expected to reach USD 17.2 billion by 2034
Alzheimer's Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72097
For decades, treatment relied on symptomatic therapies such as cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine). However, recent approvals of disease-modifying drugs (DMDs) targeting amyloid-beta, including aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab, mark a new era in Alzheimer's care. Coupled with advancements in biomarker diagnostics, digital cognitive monitoring, and personalized neurology, the Alzheimer's disease market is entering a transformative decade.
Market Overview
• Market Size 2024: USD 5.8 billion (estimated)
• Forecasted Market Size 2034: USD 17.2 billion
• CAGR (2024-2034): 11.4%
Key Highlights
• Growing global prevalence, with over 55 million people currently living with dementia.
• Expanding adoption of amyloid-targeting monoclonal antibodies.
• Rising investments in early diagnosis, imaging, and biomarker testing.
• Integration of digital health platforms and AI-driven cognitive assessments.
Segmentation Analysis
By Product
• Symptomatic therapies
o Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
o NMDA receptor antagonists (memantine)
• Disease-modifying drugs (DMDs)
o Aducanumab (Aduhelm)
o Lecanemab (Leqembi)
o Donanemab (pipeline, Eli Lilly)
• Pipeline therapies
o Tau-targeting agents
o Anti-inflammatory drugs
o Neuroprotective and regenerative therapies
• Supportive care products
o Digital monitoring platforms
o Cognitive rehabilitation tools
By Platform
• Hospital pharmacies
• Retail pharmacies
• Specialty neurology clinics
• Online pharmacies
By Technology
• Monoclonal antibodies (mAbs)
• Small-molecule CNS drugs
• Biomarker-based diagnostics (CSF, PET, blood-based assays)
• AI-driven cognitive and behavioral monitoring
• Digital therapeutics
By End Use
• Hospitals and neurology centers
• Memory clinics and specialty Alzheimer's centers
• Homecare and digital tele-neurology platforms
By Application
• Early-stage Alzheimer's disease (mild cognitive impairment)
• Moderate Alzheimer's disease
• Severe Alzheimer's disease
Summary:
The current market is dominated by symptomatic therapies, but amyloid-targeting DMDs, tau therapies, and digital monitoring represent the next phase of Alzheimer's management.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72097/alzheimer-s-disease-market
Regional Analysis
North America
• Largest market share in 2024, driven by high disease prevalence, strong adoption of Leqembi and Aduhelm, and advanced diagnostic infrastructure.
• U.S. government funding through the NIH and CMS coverage decisions boosting therapy uptake.
Europe
• Major adoption in Germany, France, and the UK, with EMA approval of new monoclonal antibodies shaping growth.
• Strong investments in dementia research and early detection programs.
Asia-Pacific
• Fastest-growing region (CAGR ~12.7%), with rising elderly populations in Japan, China, and India.
• Expanding access to biomarker testing and international Alzheimer's clinical trials.
Middle East & Africa
• Limited diagnosis and treatment infrastructure but improving with awareness campaigns.
• Growing private healthcare investment in GCC nations.
Latin America
• Brazil and Mexico lead in regional adoption, with increasing private hospital participation and access to generics.
• Rising prevalence of dementia linked to aging demographics.
Summary:
North America and Europe dominate Alzheimer's disease treatment adoption today, but Asia-Pacific is expected to see the fastest growth, driven by demographics, healthcare investments, and expanding clinical trials.
Market Dynamics
Key Growth Drivers
• Growing global prevalence of Alzheimer's due to aging populations.
• Increasing adoption of disease-modifying monoclonal antibodies.
• Expanding access to early diagnostic imaging and biomarker testing.
• Strong rare-disease and dementia-focused government funding.
Key Challenges
• High costs of new biologics such as Leqembi and Aduhelm.
• Safety concerns (e.g., amyloid-related imaging abnormalities, ARIA).
• Limited curative options-current therapies slow progression but don't reverse decline.
• Underdiagnosis and lack of access in developing regions.
Latest Trends
• Growing research into tau-targeted therapies alongside amyloid drugs.
• Increasing use of AI-based cognitive monitoring and digital biomarkers.
• Development of blood-based Alzheimer's diagnostics for earlier detection.
• Integration of real-world evidence registries to evaluate long-term therapy outcomes.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72097
Competitor Analysis
Major Players
• Biogen Inc. (Aduhelm - aducanumab)
• Eisai Co., Ltd. (Leqembi - lecanemab)
• Eli Lilly and Company (donanemab - late-stage pipeline)
• Roche Holding AG (gantenerumab, CNS portfolio)
• Novartis AG (neurodegeneration pipeline)
• Johnson & Johnson (tau-targeting research)
• Pfizer Inc. (neurology R&D)
• AbbVie Inc. (CNS portfolio)
• Merck & Co., Inc. (neurodegenerative disease pipeline)
• Emerging biotech companies focused on tau therapies, neuroinflammation, and regenerative medicine.
Summary:
The Alzheimer's disease market is consolidated around amyloid-targeting biologics, but competition is rising with tau-targeting therapies, AI-based diagnostics, and digital health solutions.
Conclusion
The Alzheimer's disease market is projected to grow from USD 5.8 billion in 2024 to USD 17.2 billion by 2034, at a CAGR of 11.4%. With the advent of disease-modifying drugs, improved diagnostics, and digital health integration, the field is moving toward earlier, more precise, and more effective interventions.
Key Takeaways:
• North America dominates today, while Asia-Pacific grows fastest.
• Market shifting from symptomatic therapy to disease-modifying biologics.
• Challenges include high costs, side effects, and access disparities.
• Competition is intensifying in amyloid- and tau-targeted therapies, biomarker diagnostics, and digital therapeutics.
Looking ahead, Alzheimer's disease care will transition from late-stage symptomatic management to early detection and disease modification, supported by AI-driven tools and precision medicine, offering renewed hope to millions of patients and families worldwide.
This report is also available in the following languages : Japanese (アルツハイマー病市場), Korean (알츠하이머병 시장), Chinese (阿尔茨海默病市场), French (Marché de la maladie d'Alzheimer), German (Alzheimer-Markt), and Italian (Mercato della malattia di Alzheimer), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72097/alzheimer-s-disease-market#request-a-sample
Our More Reports:
NLP in Healthcare and Life Sciences Market
https://exactitudeconsultancy.com/reports/73502/nlp-in-healthcare-and-life-sciences-market
Single-Cell Omics Market
https://exactitudeconsultancy.com/reports/73503/single-cell-omics-market
DNA Read Write and Edit Market
https://exactitudeconsultancy.com/reports/73504/dna-read-write-and-edit-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Market is expected to reach USD 17.2 billion by 2034 here
News-ID: 4189330 • Views: …
More Releases from Exactitude Consultancy
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Dementia with Lewy Bodies (DLB) Market is expected to reach 6.8 million by 2034
Dementia with Lewy bodies (DLB) is the second most common form of progressive dementia after Alzheimer's disease, accounting for 10-15% of dementia cases worldwide. It is characterized by the abnormal buildup of alpha-synuclein proteins (Lewy bodies) in the brain, leading to cognitive decline, fluctuations in alertness, Parkinsonian motor symptoms, sleep disturbances, and hallucinations.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72099
The complexity of DLB often leads to underdiagnosis or…
Epilepsy Patient Pool Analysis Market to Reach 92 Million Patients by 2034
Epilepsy is one of the most common chronic neurological disorders, affecting more than 65 million people worldwide. Characterized by recurrent, unprovoked seizures due to abnormal brain activity, epilepsy significantly impacts patients' quality of life and creates social, educational, and economic challenges. While the condition affects all ages, it is especially common among children and elderly populations, where diagnosis and management can be particularly complex.
Download Full PDF Sample Copy of Market…
Acute Ischemic Stroke (AIS) Market is expected to reach USD 17.5 billion by 2034
Acute ischemic stroke (AIS) is a life-threatening neurological emergency caused by the obstruction of blood flow to the brain, accounting for nearly 85% of all stroke cases worldwide. Stroke remains a leading cause of death and long-term disability, affecting millions annually and placing an immense burden on healthcare systems.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72103
Over the past two decades, treatment has advanced significantly with intravenous thrombolysis (IV…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
